Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Author(s):
Zwaginga, J.J.; Holt, B. van der; Boekhorst, P.A. te; Biemond, B.J.; Levin, M.D.; Griend, R. van der; Brand, A.; Zweegman, S.; Pruijt, H.F.M.; Novotny, V.M.J.; Vreugdenhil, A.; Groot, M.R. de; Weerdt, O. de; Pampus, E.C.M. van; Maanen-Lamme, T.M. van; Wittebol, S.; Schipperus, M.R.; Silbermann, M.H.; Huijgens, P.C.; Luten, M.; Hollestein, R.; Brakenhoff, J.A.C.; Schrama, J.G.; Valster, F.A.A.; Velders, G.A.; Koene, H.R.; Dutch HOVON 64 Study Grp
Published
2015
Publication type
Article / Letter to editor
immune thrombocytopeniarituximabsplenectomy delayingearly responseopen label phase II
Date issued
2015-03-31
Language
English
Is part of
Haematologica (2015), Vol. 100, no. 3, p. E90-E92
hdl
1887/101353
doi
10.3324/haematol.2014.110213